Skip to main content
Clinical Trials/NCT07295093
NCT07295093
Completed
Not Applicable

Association Between Age at Menopause and Levels of Anxiety and Depression

Ankara City Hospital Bilkent1 site in 1 country136 target enrollmentStarted: December 15, 2024Last updated:

Overview

Phase
Not Applicable
Status
Completed
Enrollment
136
Locations
1
Primary Endpoint
Beck Anxıety Inventory (BAI), Anxiety level

Overview

Brief Summary

Menopause is defined as the permanent cessation of menstrual cycles due to ovarian follicle depletion, typically occurring after age 50, and is associated with decreased estrogen levels. Primary ovarian insufficiency (POI) involves early ovarian dysfunction before age 40, with infertility as a key concern. Both menopause and POI may contribute to psychological symptoms, including anxiety and depression, influenced by sociodemographic and health factors. While literature reports anxiety in middle-aged women, data on its association with menopausal timing are limited. This study aims to compare women with POI and those undergoing natural menopause after age 40, assessing the relationship between age at menopause, anxiety, and depression, as well as the impact of fertility expectations on psychological well-being in POI patients.

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Ages
24 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Healthy women over 24 years of age who visited our hospital for routine outpatient check-ups, had been diagnosed with menopause, and had no history of psychiatric disorders before menopause.

Exclusion Criteria

  • Cardiovascular diseases including hypertension
  • Type 1 or type 2 diabetes mellitus
  • Morbid obesity
  • Primary adrenal insufficiency
  • Uterine fibroids
  • Thyroid dysfunctions including Hashimoto thyroiditis and Grave's disease
  • Hepatic dysfunctions
  • Renal insufficiency
  • Genetic disorders in chromosome constitution or karyotype analysis including monosomy X, trisomy X and gene mutations as BMP15, FMR I, POFIB, and GDF9
  • Neurologic diseases

Outcomes

Primary Outcomes

Beck Anxıety Inventory (BAI), Anxiety level

Time Frame: Baseline (single assessment at enrollment during routine clinic visit).

Anxiety severity measured by the Beck Anxiety Inventory (BAI) during routine clinic visit.

State-Trait Anxiety Scale (STAI) 1-2, Anxiety level

Time Frame: Baseline (single assessment at enrollment during routine clinic visit).

Anxiety severity measured by the State-Trait Anxiety Inventory (STAI) forms 1 and 2 during routine clinic visit.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Merve Didem Eşkin Tanrıverdi

Medical Doctor

Ankara City Hospital Bilkent

Study Sites (1)

Loading locations...

Similar Trials